Post-Earnings Analyst Review - St. Jude Medical

LONDON, October 22, 2014 /PRNewswire/ --

Investor-Edge.com has issued free post-earnings analyst review on St. Jude Medical Inc. (NYSE: STJ). On October 15, 2014, the company reported its financial results for Q3 FY14 (period ended September 27, 2014). Click on http://www.investor-edge.com/FreeReports to read our free earnings review on St. Jude Medical Inc. During Q3 FY14, St. Jude Medical Inc.'s net sales and adjusted net earnings per share grew 3% and 8%, respectively on a Y-o-Y basis, while GAAP diluted EPS decreased $0.08 from the preceding year quarter. Our free coverage report can be accessed at:

http://www.investor-edge.com/register

Earnings Overview 

During Q3 FY14, St. Jude Medical Inc. reported net sales of $1,372 million, compared to $1,338 million in the same period last year. The company's net sales during the reported quarter came marginally below the Bloomberg analysts' forecast of $1,382 million. In Q3 FY14, the company recognized net after-tax charges of $39 million, or $0.14 per share, mainly related to product field actions, impairment charges and restructuring activities. Including these items, the company's net income narrowed to $238 million, or $0.82 per diluted share in Q3 FY14, from $262 million, or $0.90 per diluted share in the same quarter last year. Analysts from Bloomberg had expected the company to report net income of $242 million, or $0.83 per share in Q3 FY14. The company's adjusted net income broadened to $281 million, or $0.97 per diluted share in Q3 FY14, from $262 million, or $0.90 per diluted share in the corresponding quarter last year. The free research on STJ can be downloaded as in PDF format at:

http://www.Investor-Edge.com/STJFreeReport

Daniel J. Starks, Chairman, President and CEO of St. Jude Medical Inc. commented that during Q3 2014, sales growth accelerated in the U.S. due to the strength of the company's innovation and new products such as its CardioMEMS heart failure monitoring system. However, sales growth in the company's international markets was slower than expected and the company has adjusted its outlook for the Q4 2014 accordingly. Mr. Starks added that the company remains firmly committed to delivering an innovation-based growth program that adds significant value to the health care system by improving patient care while reducing costs.

The company has given its guidance for the fourth quarter and full-year FY 2014. In its guidance for Q4 FY14, the company expects revenue to be in the range of $1.385 billion to $1.465 billion and consolidated adjusted EPS to be between $1.02 and $1.04 per share. Further, for full-year FY 2014 the company expects total revenue to be in the range of $5.568 billion to $5.648 billion and consolidated adjusted EPS to be between $3.97 and $3.99. Sign up and read the free analyst's notes on STJ at:

http://www.Investor-Edge.com/STJ-22102014

Stock Performance 

On the day of the earnings release, October 15, 2014, St. Jude Medical Inc.'s stock plummeted 4.39% to end the session at $57.28. The stock however recovered its losses over the last three trading days, gaining 1.75% on the last close, Tuesday, October 21, 2014, where it finished at $59.99, after vacillating between $59.10 and $60.11. A total of 1.92 million shares were traded, which was above its three months average volume of 1.63 million shares. Over the previous three trading sessions, the company's shares have advanced 5.73%. However, the stock has fallen by 3.62% over the last one month and 3.16% from the beginning of 2014. Shares in St. Jude Medical Inc. are trading below their 50-day and 200-day moving averages of $62.75 and $64.78, respectively. Furthermore, the stock traded at a PE ratio of 15.52 and has a Relative Strength Index (RSI) of 40.07. Visit Investor-Edge and access the latest research on STJ at:

http://www.Investor-Edge.com/STJEarningsCoverage

Sneak Peek to Corporate Insider Trading 

In the last one month St. Jude Medical Inc. has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on STJ is available at:

http://www.Investor-Edge.com/STJInsiderTrading

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED